Research programme: non-nucleoside hepatitis C antivirals - BioWest

Drug Profile

Research programme: non-nucleoside hepatitis C antivirals - BioWest

Latest Information Update: 27 Jun 2012

Price : $50

At a glance

  • Originator MIGENIX
  • Class Small molecules
  • Mechanism of Action Hepatitis B virus replication inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 19 Aug 2011 Discontinued - Preclinical for Hepatitis C in Canada (PO)
  • 08 Jun 2007 Preclinical development is ongoing
  • 18 Apr 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top